Accessibility StatementSkip Navigation MISSISSAUGA, ON, Nov. 11, 2025 /PRNewswire/ - Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) (the "Company" or "Cymat") is pleased to announce that it will be hosting an Investor Update call and presentation on Wednesday, November 12 at 2:00 p.m. EDT, with details outlined in this release. The purpose of the call is to provide investors with a corporate update on the numerous ongoing projects, programs and initiatives Cymat is currently undertaking. The Company wil ...

The terms of this Offering are subject to approval from the TSX Venture Exchange and closure of this Offering will occur only after said approval is obtained. Accessibility StatementSkip Navigation MISSISSAUGA, ON, Oct. 21, 2025 /PRNewswire/ - Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) (the "Company" or "Cymat"). Today Cymat provided an update regarding a non-brokered private placement of equity Units (the "Offering"), previously announced on October 2, 2025. Subject to approval from the TSX Ventur ...

Accessibility StatementSkip Navigation MISSISSAUGA, ON, Oct. 2, 2025 /PRNewswire/ - Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) (the "Company" or "Cymat"). Today Cymat announced that it has completed a non-brokered private placement of equity Units (the "Offering"), generating gross proceeds of $1,499,500. Each Unit was priced at $0.13 with one Unit consisting of one (1) Common Share and one (1) Common Share Purchase Warrant. Each Warrant entitles the holder to purchase one Common Share at a price o ...

Core Insights - Cymat Technologies Ltd. has entered into a Letter of Intent with Rio Tinto Alcan Inc. to acquire technology and know-how for manufacturing proprietary aluminum metal matrix composites (MMC) [1][2] - The acquisition is part of RTA's strategic reorganization as they exit the MMC business, which they have operated for over 40 years [2][4] - Cymat plans to establish MMC production capabilities at its Mississauga plant, leveraging existing resources and workforce [3][5] Financial Overview - Historical sales volumes from RTA suggest that Cymat could achieve incremental annual revenue between $7.5 million and $10 million, with margins comparable to or better than its AlusionTM product [4] - Estimated capital costs for equipment are projected to be between $2 million and $2.5 million, with technology transfer expenses expected to be in the low to mid six-figure range [4] - Cymat intends to finance this initiative through existing outstanding warrant proceeds and equipment financing sources [4] Strategic Benefits - The new business line will provide Cymat with a substantial, uncorrelated, and predictable revenue stream, enhancing profitability [5] - It will also reduce the cost of Cymat's primary input material significantly, making the company more price-competitive in the automotive sector [5][6] - The initiative is expected to accelerate Cymat's path to substantial profitability, particularly with anticipated sales growth in the nuclear and military sectors [6]